A Phase 2 Study to Evaluate HM15275 in Obese or Overweight Subjects Without Diabetes Mellitus

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

250

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

January 31, 2027

Study Completion Date

January 31, 2027

Conditions
ObeseObesity
Interventions
DRUG

HM15275

HM15275 is a sterile solution for subcutaneous injection, supplied pre-filled syringes.

DRUG

Placebo of HM15275

A sterile, matching solution supplied in pre-filled syringes.

Trial Locations (12)

27103

Accellacare of Winston Salem, Winston-Salem

27511

Accellacare of Cary - Cary Medical Group, Cary

27609

Raleigh Medical Group, P.A., Raleigh

28401

Accellacare of Wilmington, LLC, Wilmington

28601

Accellacare of Hickory, Hickory

28626

Accellacare of Piedmont - Piedmont HealthCare, Statesville

29464

Accellacare of Charleston, Mt. Pleasant

37620

Accellacare of Bristol-PAC of Tennessee, Bristol

Bristol-Internal Medicine and Pediatric Associates of Bristol, P.C., Bristol

50010

Accellacare of McFarland, Ames

60453

Accellacare of Duly - Duly Oak Lawn, Oak Lawn

75230

Velocity Clinical Research, Dallas, Dallas

All Listed Sponsors
lead

Hanmi Pharmaceutical Company Limited

INDUSTRY